08/2004 Press Release

Proceeds to fund lead product candidates in oncology and HIV

Paris – August 30, 2004 –BioAlliance Pharma SA, a privately held biopharmaceutical company focused on the field of drug resistance, today announced that it has raised an additional 2.0 million euros (2.4 million dollars) to top off its third round of financing at 12 million euros (14.7 million dollars). In a round led by Auriga Partners, the additional investment came from Siparex Ventures, the venture capital arm of one of the leading private equity management companies in France. Two other new investors, ING, the Dutch bank and insurance company, and the French Co-Investment Fund (FCJE) also participated in the round along with previous investors Capricorn Venture Partners, ABN-AMRO Capital France, and SPEF Ventures. Pascal Demichel, Senior Investment Manager at Siparex Ventures, joins the BioAlliance Pharma Supervisory Board as a result of this investment.

“The quality of the new investors and the ongoing commitment of our previous investors is a significant vote of confidence in our development programs,” said Dominique Costantini, BioAlliance Co-Founder, President and CEO. “We are very pleased to have attracted a firm as outstanding as Siparex Ventures to complete this round of financing and are gratified for the support shown by our investors in the BioAlliance business model.”

The proceeds will enable BioAlliance to fund the development of a portfolio of drug candidates, including its Miconazole-Lauriad(TM) product. This is a once-a-day buccal bio-adhesive tablet developed to provide improved anti-fungal therapy for treatment of oropharyngeal candidiasis in a broad range of immune compromised patients, including cancer and HIV patients receiving chemotherapy or immuno-suppressive drugs, insulin dependent diabetics and the elderly. Miconazole-Lauriad(TM) is currently in two Phase III clinical trials in Europe, one in HIV patients and the other in head and neck cancer patients following radiotherapy. The Company intends to file an IND later this year to conduct a Phase III clinical study in the U.S.

The funding will also support advancement of Doxorubicin-Transdrug(TM), based on the Company’s proprietary nanoparticle technology. Doxorubicin-Transdrug(TM) is currently in a Phase I/II trial being conducted at clinical sites in France for treatment of primary liver cancer, hepatocellular carcinoma (HCC).

“We are very excited to be investors in BioAlliance,” said Pascal Demichel. “BioAlliance combines a powerful proprietary product pipeline with a stellar management team and we are confident that the Company will develop into one of the truly significant biopharmaceutical success stories in Europe.”

“The Lauriad and Transdrug programs, together with the NCEs which the company has acquired in oncology and HIV, make for an enormously exciting product potential that may represent a significant advance for cancer and HIV patients,” noted Olivier Younès, Senior Associate, Siparex Ventures. “BioAlliance has unique access to potentially best-in-class projects and is leveraging that access to develop a potent pipeline of products.”

About BioAlliance Pharma
BioAlliance Pharma is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapeutics and predictive assays in the field of drug resistance, targeting cancer and infectious diseases, including in particular HIV. The Company has a balanced portfolio of products and proprietary technologies in various stages of development, from preclinical research to a product approved for marketing. To supply this pipeline of products, BioAlliance maintains a unique network of alliances with leading academic investigators from French research institutions, including the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Médicale (Inserm) and the Institut Pasteur, among others. For additional company background, please visit the BioAlliance Pharma web sites at: www.BioAlliancepharma.com and www.viralliance.com.

About Sigefi Ventures Gestion (Siparex Ventures)

Sigefi Ventures Gestion manages 242 million euros in assets, including 42 million euros in the US, where the group has been operating for 17 years. Investments are concentrated predominantly in the sectors of Information Technology, Security and the Life Sciences.

Sigefi Ventures Gestion is the venture capital subsidiary of Sigefi Private Equity (Siparex group), one of the leading independent private equity investors in France, with 813 million euros assets under management. The team in charge of venture capital investments, with bases in Paris, Lyon and San Mateo, California, is made up of eleven professionals, some with more than 15 years of experience in the field.

For more information: www.siparex.com
Contact: Pascal Demichel 33 (0)1 53 93 02 20

For additional company background, click here.

Company Contact

Richard Keatinge
Vice President, Business Development
BioAlliance Pharma SA
Tel : +33 (0) 1 45 58 76 00
richard.keatinge@bioalliancepharma.com

Media Contact
Andrew Lloyd & Associates
Andrew Lloyd
Tel : +44 1 273 675100
Gilles Petitot
Tel : +33 1 56 54 07 00